SCHEMBL5849064

SCHEMBL5849064

CCOC(=O)CC(CC(=O)CCl)c1cc(OC)cc(OC)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.45
FGFR2 P21802 3/20 0.39
FGFR3 P22607 2/20 0.38
FGFR1 P11362 1/20 0.38
FGFR4 P22455 1/20 0.38
KDR P35968 1/20 0.38
ALDH1A1 P00352 2/20 0.38
CYP3A4 P08684 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.37
MAPK1 P28482 2/20 0.36
TSHR P16473 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
F2 P00734 1/20 0.36
F10 P00742 1/20 0.36
THRB P10828 1/20 0.35
TACR1 P25103 1/20 0.35
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23802065 0.82 ALDH1A1 (0.36) ALDH1A1F2F10KMT2AHTT
SCHEMBL5847519 0.78 F2 (0.46) SMN1; SMN2ALDH1A1TSHRL3MBTL1F2
SCHEMBL8770968 0.78 SMN1; SMN2 (0.50) SMN1; SMN2FGFR2FGFR3FGFR1FGFR4
SCHEMBL5848181 0.77 F2 (0.45) SMN1; SMN2ALDH1A1CYP3A4TSHRL3MBTL1
SCHEMBL5847662 0.77 HTT (0.46) ALDH1A1MAPK1F2F10HTT
SCHEMBL10665829 0.76 L3MBTL1 (0.56) ALDH1A1HPGDALOX15L3MBTL1F2
SCHEMBL5847966 0.76 F10 (0.39) SMN1; SMN2ALDH1A1HPGDTSHRF2
SCHEMBL5847855 0.76 KDM4E (0.43) SMN1; SMN2ALDH1A1F2F10POLB
SCHEMBL5847413 0.75 F10 (0.44) SMN1; SMN2ALDH1A1MAPK1F2F10
SCHEMBL8311872 0.74 TNF (0.32) L3MBTL1TACR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115596-B2 Thiazole compounds as integrin receptor antagonists derivatives PHARMACIA CORPORATION (US) 2006-10-03 US disclosed
EP-1572690-A1 THIAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES Pharmacia Corporation (US) 2005-09-14 EP disclosed
US-20050004189-A1 Thiazole compounds as integrin receptor antagonists derivatives PHARMACIA CORPORATION 2005-01-06 US disclosed
WO-2004058760-A1 THIAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES PHARMACIA CORPORATION (US) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004189-A1 Thiazole compounds as integrin receptor antagonists derivatives ITGA5, ITGB5, ITGAL SMN1; SMN2 3343/4885FGFR2 620/4885FGFR3 538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.